A. Sureda Balari

Evolution of Outcome over Time for Relapsed Hodgkin Lymphoma after Autologous Stem Cell Transplant: Improved Survival for Early Relapse in Recent Years

J. Briones, S. Montoto, D. Blaise, 2020 .

Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study

S. Iida, C. Touzeau, A. Chari, 2020, British journal of haematology.

Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma

J. de la Rubia, M. Mateos, L. Palomera, 2020, HemaSphere.

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

H. Goldschmidt, A. Oriol, P. Moreau, 2023, Blood Cancer Journal.

A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody).

A. Krishnan, D. Reece, R. Wäsch, 2022, Journal of Clinical Oncology.

Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.

C. Carlo-Stella, M. Hutchings, E. Clark, 2022, Journal of Clinical Oncology.

Phase 3 trial (GCT3013-05) of epcoritamab versus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

P. Zinzani, P. Lugtenburg, S. Y. Kim, 2021 .